Shares of Janux Therapeutics (JANX) were rallying Tuesday after the biopharmaceutical company reported late Monday positive interim clinical data for its JANX007 clinical program in prostate cancer patients.
The company said high prostate-specific antigen response rates and deep PSA declines were observed in all doses in the phase 1a clinical trial, which also showed that JANX007 has a well-tolerated safety profile.
Janux said that based on these results, two once-weekly step dose regimens have been identified for phase 1b expansion trials.
Price: 61.56, Change: +21.38, Percent Change: +53.21
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。